within Pharmacolibrary.Drugs.ATC.C;

model C05AD06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.16666666666666666,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oxetacaine is a potent local anesthetic mainly used in combination with antacids for the symptomatic relief of gastritis, peptic ulcer, and esophagitis. It is generally formulated as an oral suspension, often together with antacids to treat stomach pain and indigestion. It is not widely approved in Western countries, but used in parts of Asia.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data available; PK parameters estimated from drug class and related local anesthetics, intended for an orally administered adult; these are rough estimates.</p><h4>References</h4><ol><li>M Ahsan Shaker, Naveed Akhtar, Muhammad Usman Minhas, Kifayat Ullah Khan, Muhammad Imad-Ud-Din Zangi, Abubakar Munir,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen.,Drug research,2020<a href='https://pubmed.ncbi.nlm.nih.gov/32110819/'>https://pubmed.ncbi.nlm.nih.gov/32110819/</a></li><li>Hokuto Namba, Yuki Nishimura, Norimitsu Kurata, Mariko Iwase, Takahito Hirai, Yuji Kiuchi,Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.,Biological & pharmaceutical bulletin,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28867721/'>https://pubmed.ncbi.nlm.nih.gov/28867721/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C05AD06;
